Internship

Biology Co-Op

Confirmed live in the last 24 hours

Kymera Therapeutics

Kymera Therapeutics

201-500 employees

Develops targeted protein degradation therapies

Biotechnology
Healthcare

Belmont, MA, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis

You match the following Kymera Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Currently pursuing a BS degree in a biology, biochemistry, cell and molecular biology or a related field.
  • Hands-on laboratory experience in cellular and molecular biology and or biochemistry.
  • Ability to work well in a collaborative environment and on teams.
  • Comfortable presenting experimental results and plans to small groups and cross functional teams.
Responsibilities
  • Independently execute experiments to test compounds in human or mouse primary immune cell activation assays that include flow, PCR and cytokine readouts.
  • Perform data analysis and interpretation using software tools including graphpad prism.
  • Isolate and characterize primary cells for banking in immunology inventory.
  • Meet regularly with mentor to discuss action items and experimental design, participate and present in group and project meetings.
  • Document research activities and findings in electronic laboratory notebook and maintain meticulous records of experimental strategies.
Desired Qualifications
  • Ideally will have taken a course in immunology and/or advanced cellular/molecular biology.

Kymera Therapeutics develops treatments by targeting and breaking down specific proteins that contribute to diseases, particularly cancer and immune disorders. Their main technology, the Pegasus Platform, enables them to identify these harmful proteins and create drug candidates aimed at effectively treating various conditions. Unlike many competitors, Kymera focuses on targeted protein degradation, which can lead to more precise therapies. The company's goal is to create next-generation medicines that address unmet medical needs, supported by partnerships with organizations like Sanofi to enhance their research and development efforts.

Company Stage

IPO

Total Funding

$191.6M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Simplify Jobs

Simplify's Take

What believers are saying

  • Kymera raised $225M and $275M in public offerings, boosting financial resources.
  • HSBC's investment indicates strong confidence in Kymera's business model and prospects.
  • Partnership with Neosphere Biotechnologies opens new therapeutic opportunities in molecular glue discovery.

What critics are saying

  • Increased competition in protein degradation could impact Kymera's market share.
  • Regulatory scrutiny may delay clinical trials and drug approval timelines.
  • Dependence on key partnerships like Sanofi could affect revenue if altered.

What makes Kymera Therapeutics unique

  • Kymera's Pegasus Platform enables precise identification and degradation of disease-causing proteins.
  • The company focuses on targeted protein degradation, a novel approach in drug development.
  • Kymera's strategic partnership with Sanofi enhances its credibility and market reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options